FBK on Forbes

Forbes Italia published a feature on public tenders in Life Sciences: a high-value process that moves billions every year, gets little attention, and is only now being transformed by vertical AI.

In Europe, around 70% of medical technology is bought through public tenders, according to MedTech Europe. It is one of the most complex and highest-value commercial processes that exist, and in 2026 it is still largely manual. Handling it better is not only about saving time; it shapes where and how a company competes.

• Public tenders are among the highest-value and least digitized processes in the sector.
• With AI models now a commodity, the difference comes down to domain expertise, proprietary data, and integration into the process.
• This is where vertical AI stops being a promise and becomes a competitive advantage.

Read the full article on Forbes

We are working to make tender management a strategic lever, not an operating cost.